TargED Biopharma strengthens its Board of Directors along with raising €39m Series A financing

– NETHERLANDS, Utrecht –  TargED Biopharmaceuticals, a private biotechnology company focused on developing improved treatments for thrombotic diseases, today announced it has raised Series A financing of EUR 39 million led by an international syndicate comprising Andera Partners, Fund+, Hadean Ventures, Inkef Capital, and Sunstone Life Science Ventures, and joined by existing investors FIRST, Curie Capital and Utrecht Health Seed Fund.

Following the closing of the financing, the Board of TargED will include

• Thijs Cohen Tervaert, Inkef Capital (Chair),
• Olivier Litzka, Andera Partners,
• Mariette van der Velden-Roesink, Curie Capital,
• Jan Van den Bossche, Fund+,
• Roger Franklin, Hadean Ventures
• Jacob Lange Moresco, Sunstone Life Science Ventures.

“Together with Jacob, Roger, Jan and Olivier, we are very pleased to invest in this impressive TargED team. Microlyse is a therapeutic innovation that has a very strong potential to significantly lower the burden of disease related to thrombotic events. We are excited to join forces with TargED to accelerate the development of Microlyse into clinical development, both in aTTP and AIS.” said Board Chair, Thijs Cohen Tervaert.

The new funding will accelerate the development of its lead compound, Microlyse. TargED will focus development on two initial indications: acquired Thrombotic Thrombocytopenia Purpura and Acute Ischemic Stroke.

Kristof Vercruysse, CEO, said: “We are delighted to have the support of this international syndicate of world-class life science investors, a validation of the potential of Microlyse. We are proud to be developing products that have the potential to positively impact millions of lives by enabling patient access to such lifesaving treatment.”

“We are happy that our pioneering efforts on the design of an enzyme that targets blood clots led to compelling preclinical data recently published in the journal Blood” said UMC Utrecht Associate Professor Coen Maas and scientific co-founder of TargED. “It is exciting to see that this work has been able to attract such a strong syndicate of investors, which will now allow us to develop Microlyse towards therapeutic breakthrough, potentially across a range of indications with high unmet medical need”.

Mariette van der Velden, Managing Partner of Curie Capital, commented: “Microlyse has the potential to better address the needs of patients suffering from thrombotic diseases. With a tremendous drive, the TargED team has produced very promising preclinical results supported by our seed funding. We are excited to enter the next phase of the development of Microlyse towards patients worldwide.”

About TargED

TargED Biopharmaceuticals B.V. is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura and Acute Ischemic Stroke. The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

TargED, a spin-off of the University Medical Center Utrecht, was founded in July 2020 by Associate Professor at the Department of Clinical Chemistry and Haematology, Coen Maas, Ph.D., an expert in thrombosis and hemostasis, Steven de Maat, Ph.D., an expert in recombinant protein development and optimization, Marc van Moorsel, a researcher with a focus on Acute Ischemic Stroke and Kristof Vercruysse, with more than 20 years of experience in bringing biopharmaceutical compounds from pre-clinical proof of concept to market, most notably, Caplacizumab for Thrombotic Thrombocytopenic Purpura at Ablynx between 2007 and 2013.

For more information: https://www.targedbiopharmaceuticals.com/